Skip to main content

Table 1 Preoperative clinical characteristics of SGC and MGC in the entire cohort (n = 4107) and after propensity score matching (n = 665)

From: Clinicopathological features and impact of adjuvant chemotherapy on the long-term survival of patients with multiple gastric cancers: a propensity score matching analysis

Parameters Entire cohort (before matching) P value Propensity score matched cohort P value
SGC, n (%) MGC, n (%) SGC, n (%) MGC, n (%)
Age (years)    0.141    0.968
 ≤ 60 1871 (47.1) 54 (40.6)   215 (40.4) 54 (40.6)  
 > 60 2103 (52.9) 79 (59.4)   317 (59.6) 79 (59.4)  
Sex    0.166    0.886
 Male 2924 (73.6) 105 (78.9)   423 (79.5) 105 (78.9)  
 Female 1050 (26.4) 28 (21.1)   109 (20.5) 28 (21.1)  
BMI (kg/m2)    0.467    0.947
 BMI < 18.5 385 (9.7) 13 (9.8)   57 (10.7) 13 (9.8)  
 18.5 ≤ BMI < 25 2921 (73.5) 103 (77.4)   406 (76.3) 103 (77.4)  
 BMI ≥ 25 668 (16.8) 17 (12.8)   69 (13.0) 17 (12.8)  
Family historya    0.273    0.269
 Absent 3736 (94.0) 126 (94.7)   518 (97.3) 126 (94.7)  
 Gastric cancer 128 (3.2) 6 (4.5)   11 (2.1) 6 (4.5)  
 Other malignancy 110 (2.8) 1 (0.8)   3 (0.6) 1 (0.8)  
Tobacco use    0.754    0.965
 No 2849 (71.7) 97 (72.9)   389 (73.1) 97 (72.9)  
 Yes 1125 (28.3) 36 (27.1)   143 (26.9) 36 (27.1)  
Alcohol use    0.410    0.532
 No 3657 (92.0) 125 (94.0)   507 (95.3) 125 (94.0)  
 Yes 317 (8.0) 8 (6.0)   25 (4.7) 8 (6.0)  
ASA score    0.168    0.641
 I 1954 (49.2) 57 (42.9)   241 (45.3) 57 (42.8)  
 II 1818 (45.7) 71 (53.4)   269 (50.6) 71 (53.4)  
 III 193 (4.9) 4 (3.0)   21 (3.9) 4 (3.0)  
 IV 9 (0.2) 1 (0.8)   1 (0.2) 1 (0.8)  
Comorbiditiesb    0.464    0.715
 Absent 1226 (30.9) 88 (66.2)   343 (64.5) 88 (66.2)  
 Present 2748 (69.1) 45 (33.8)   189 (35.5) 45 (33.8)  
cT stage    0.920    0.785
 T1–T3 2074 (52.2) 70 (52.6)   287 (53.9) 70 (52.6)  
 T4 1900 (47.8) 63 (47.4)   245 (46.1) 63 (47.4)  
cN stage    0.050    0.806
 N0 1653 (41.6) 44 (33.1)   182 (34.2) 44 (33.1)  
 N+ 2321 (58.4) 89 (66.9)   350 (65.8) 89 (66.9)  
  1. SGC solitary gastric cancers, MGC multiple gastric cancers, BMI body mass index, ASA American Society of Anesthesiologists, cT stage clinical tumor stage, cN stage clinical node stage, cN0 clinical node-negative, cN+ clinical node-positive
  2. aFamily history presence of cancer within the patients’ first- and second- degree relatives
  3. bComorbidities including hypertension, diabetic mellitus, heart disease (coronary atherosclerotic heart disease, arrhythmia, etc.), pulmonary disease (chronic obstructive pulmonary disease, asthma, pneumonia, etc.), central nervous system disease (cerebrovascular disease, neurodegenerative disease, etc.), liver disease (cirrhosis, hepatitis, etc.), renal disease (chronic kidney disease, nephritis, etc.), anemia, hypoalbuminemia, and hyperthyroidism